Baidu
map

JCE:使用抗心律失常药物不影响房颤消融的疗效

2013-06-27 JCE dxy

环肺静脉射频消融术(Pulmonary vein isolation,PVI)是近年出现的房颤治疗新方法,主要用于药物治疗效果不佳或药物不能耐受的房颤患者。PVI治疗房颤的主要机制是电隔离肺静脉,后者被认为是心房触发灶发生的主要部位。在PVI后测定消融线是否达到完全隔离是评价消融成功的标准。多数临床中心建议患者在PVI期间仍服用抗心律失常药物,并维持至术后3个月,然而停药后房颤的复发十分常见,据统

环肺静脉射频消融术(Pulmonary vein isolation,PVI)是近年出现的房颤治疗新方法,主要用于药物治疗效果不佳或药物不能耐受的房颤患者。PVI治疗房颤的主要机制是电隔离肺静脉,后者被认为是心房触发灶发生的主要部位。在PVI后测定消融线是否达到完全隔离是评价消融成功的标准。多数临床中心建议患者在PVI期间仍服用抗心律失常药物,并维持至术后3个月,然而停药后房颤的复发十分常见,据统计复发率高达14%-80%。 目前PVI仅作为房颤消融的二线治疗,主要用于药物治疗效果不佳或不能耐受的患者,因此许多患者在进行PVI前使用过抗心律失常药物,然而目前对于PVI围手术期是否停用抗心律失常药物还存在争论,理论上PVI手术期间使用抗心律失常药物可影响消融效果的评判,但目前还缺乏临床证实,据此Dukes JW等近来在JCE上发表了一篇临床研究。 该研究共入选180例首次进行PVI的房颤患者,所有患者均来自美国约翰-霍普金斯大学医院,根据患者手术期间是否服用抗心律失常药物将患者分成两组:使用抗心律失常药物的患者127例,这些患者的平均随访时间为24.6个月;未使用抗心律失常药物的患者53

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2062816, encodeId=054020628161a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Feb 15 10:06:00 CST 2014, time=2014-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079078, encodeId=630420e9078cf, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Dec 26 04:06:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421566, encodeId=e61014215664a, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sat Jun 29 07:06:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578856, encodeId=3cfe15e885681, content=<a href='/topic/show?id=ae3a553110e' target=_blank style='color:#2F92EE;'>#抗心律失常药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55311, encryptionId=ae3a553110e, topicName=抗心律失常药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35616453470, createdName=肉我只吃一口, createdTime=Sat Jun 29 07:06:00 CST 2013, time=2013-06-29, status=1, ipAttribution=)]
    2014-02-15 achengzhao
  2. [GetPortalCommentsPageByObjectIdResponse(id=2062816, encodeId=054020628161a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Feb 15 10:06:00 CST 2014, time=2014-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079078, encodeId=630420e9078cf, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Dec 26 04:06:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421566, encodeId=e61014215664a, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sat Jun 29 07:06:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578856, encodeId=3cfe15e885681, content=<a href='/topic/show?id=ae3a553110e' target=_blank style='color:#2F92EE;'>#抗心律失常药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55311, encryptionId=ae3a553110e, topicName=抗心律失常药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35616453470, createdName=肉我只吃一口, createdTime=Sat Jun 29 07:06:00 CST 2013, time=2013-06-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2062816, encodeId=054020628161a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Feb 15 10:06:00 CST 2014, time=2014-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079078, encodeId=630420e9078cf, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Dec 26 04:06:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421566, encodeId=e61014215664a, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sat Jun 29 07:06:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578856, encodeId=3cfe15e885681, content=<a href='/topic/show?id=ae3a553110e' target=_blank style='color:#2F92EE;'>#抗心律失常药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55311, encryptionId=ae3a553110e, topicName=抗心律失常药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35616453470, createdName=肉我只吃一口, createdTime=Sat Jun 29 07:06:00 CST 2013, time=2013-06-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2062816, encodeId=054020628161a, content=<a href='/topic/show?id=14fb10264d7' target=_blank style='color:#2F92EE;'>#JCE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10264, encryptionId=14fb10264d7, topicName=JCE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e656479, createdName=achengzhao, createdTime=Sat Feb 15 10:06:00 CST 2014, time=2014-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2079078, encodeId=630420e9078cf, content=<a href='/topic/show?id=8fdb542e29e' target=_blank style='color:#2F92EE;'>#房颤消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=69, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54272, encryptionId=8fdb542e29e, topicName=房颤消融)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9b30126, createdName=skhzy, createdTime=Thu Dec 26 04:06:00 CST 2013, time=2013-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1421566, encodeId=e61014215664a, content=<a href='/topic/show?id=4bc865819d2' target=_blank style='color:#2F92EE;'>#消融#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65819, encryptionId=4bc865819d2, topicName=消融)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a193676008, createdName=xiangyuzhou972, createdTime=Sat Jun 29 07:06:00 CST 2013, time=2013-06-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578856, encodeId=3cfe15e885681, content=<a href='/topic/show?id=ae3a553110e' target=_blank style='color:#2F92EE;'>#抗心律失常药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55311, encryptionId=ae3a553110e, topicName=抗心律失常药物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c35616453470, createdName=肉我只吃一口, createdTime=Sat Jun 29 07:06:00 CST 2013, time=2013-06-29, status=1, ipAttribution=)]

相关资讯

JAMA:长检测间期程序可改善ICDs患者的结局

2013年5月8日在线发表于JAMA杂志的一项研究成果显示,可植入式复律除颤器(ICD)长检测间期编程与标准检测间期相比可减少抗心动过速起搏事件、ICD电击及不恰当电击事件。“目前,ICDs治疗是一级预防及二级预防的治疗标准。随着ICD疗法适应症的日渐扩大,有关ICD疗法有可能对患者预后及生活质量产生不良影响的忧虑也在增加。一些作者报告说,ICD疗法无论恰当与否,都与死亡及心衰风险的增加有关。为了

Am J Psychiatry:FDA关于大剂量西酞普兰警告受质疑

  美国一项研究对美国食品与药物管理局(FDA)“西酞普兰>40mg/d可能导致心律失常”的警告提出质疑。研究表明,与(1~20)mg/d相比,西酞普兰>40mg/d与室性心律失常(校正HR=0.68)、全因死亡(校正HR=0.94)、非心源性死亡(校正HR=0.90)风险较低相关,未发现其增加心源性死亡风险;西酞普兰(21~40)m

Eur Heart J:临床研究发现服用地高辛患者的死亡率增加

地高辛广泛用于房颤的控制。然而,地高辛与死亡率增加有关。是否地高辛本身的毒副作用还是用药者体质弱并且有合并症导致死亡率增加,尚不清楚。近期,美国的吉尔心脏研究所肯塔基大学的一项研究表明地高辛与房颤病人的死亡率增加密切相关,该结果发表在《欧洲心脏杂志》上。 该研究应用多元Cox比例风险模型评估了节律管理会随访调查的房颤病人死亡率与地高辛的关系。研究分析了心衰患者或非心衰患者及所有亚群,心衰定义为有

Heart Rhythm: ICD放电对成人先天性心脏病患者性功能的影响

随着植入式心脏转复除颤器(ICD)的问世,越来越多的成人先天性心脏病患者植入ICD用于心源性猝死的一级或二级预防,其主要原因包括越来越多的恶性心律失常被发现及ICD技术的日益成熟。法洛氏四联症患者是需要植入ICD的最大亚群,既往的临床研究已经涉及了ICD植入失败及ICD相关并发症的原因分析,约30%-40%的患者存在ICD的不正确放电。 虽然ICD放电可以拯救患者的生命,但是其带来的心理上的影响

Am J Cardiol:心脏复律者需密切监测药物所致心律失常

  美国一项研究表明,接受化学心脏复律(CCV)的持续性房颤患者需要对药物所致的心律失常进行更为密切的监测。论文于5月24日在线发表于《美国心脏病学杂志》(Am J Cardiol)。   多非利特为为III类抗心律失常药物,被批准用于持续性房颤患者的窦性心律维持。此项研究共纳入99例心脏复律前接受负荷量多非利特治疗的持续性房颤患者,并评估了CCV是否预示致心律失常风险升高。

JCE:特发性室颤新的心电图特征

早期复极心电图改变及J波常见于特发性室颤的患者,其发生率明显高于正常人群。近来的临床研究表明,早期复极心电图改变是特发性室颤患者发生室颤及心脏性猝死的预测因素,还有研究表明早期复极合并ST段水平型或压低与恶性心律失常发生强烈相关,因此早期复极心电图改变是特发性室颤患者的特征性心电图改变。 然而仍有许多特发性室颤患者并没有早期复极心电图改变,是否还有其他心电图特征目前还不清楚,还需要进一步临床研究

Baidu
map
Baidu
map
Baidu
map